advertisement
Abstract #47810 Published in IGR 13-4
Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe
Hollo G; Thelen U; Teus MA; Quaranta L; Ferkova S; Babic N; Misiuk-Hojlo M; Mikropoulos DG; Kaluzny BJ; Kozobolis VJournal of Ocular Pharmacology and Therapeutics 2011; 27: 493-498
Purpose: To determine the direct costs of therapy over 5 years of a European monotherapy cohort begun on a prostaglandin (PTG) versus timolol in patients with primary open-angle glaucoma or ocular hypertension. Methods: A retrospective, multicenter, active-controlled, observational study. Data were abstracted for European patients treated as initial monotherapy in 1996 or afterward, with 5 years of available records. Results: This study included 271 patients (166 on a PTG and 105 on timolol at baseline). The average cost/month/patient over 5 years was $45.47(plus or minus)12.61 for PTG and $31.50(plus or minus)15.47 for timolol (P<0.001, based on German prices). After 5 years, although there was no difference in number of glaucoma medicines prescribed between groups (1.0 PTGs and 1.1 timolol, P=0.41), the timolol group demonstrated a higher intraocular pressure (17.7(plus or minus)2.9 vs. 16.5(plus or minus)3.0mm Hg, P<0.001), more medication changes (P=0.01), greater incidence of glaucomatous progression (P=0.04), and less patients persistent on original monotherapy (P<0.001) than the PTG cohort. Conclusions: Patients originally on timolol monotherapy have a lower cost of care over 5 years than those started on a PTG. However, timolol patients during follow-up may demonstrate a higher intraocular pressure, more progression, more medication changes, and lower persistency of the original monotherapy. (copyright) 2011 Mary Ann Liebert, Inc.
W.C. Stewart. PRN Pharmaceutical Research Network, LLC, 2510 Warren St., Cheyenne, WY 82001, United States. Email: info@prnorb.com
Classification:
14 Costing studies; pharmacoeconomics
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
